More Barriers To Entry For M&A In China? Novartis Case Provides Some Clarity

HONG KONG - Much awaited regulations on how China will review inbound mergers and acquisitions in light of national security and competition suggest long waits for pending and future deals and new barriers to entry, say some business groups

More from Archive

More from Scrip